nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

Nanomedicines in Cancer Therapy

verfasst von : Enas Abu-Qudais, Balakumar Chandrasekaran, Sara Samarneh, Ghadir Kassab

Erschienen in: Integrative Nanomedicine for New Therapies

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Cancer is one of the most controversial diseases known for humanity and emerged as a global health problem all the time. The drug discovery scientists and clinicians have attempted to cure cancer since centuries. Conventional cancer treatments such as radiotherapy and chemotherapy have many limitations including low specificity, lack of stability, rapid drug clearance, biodegradation and limited targeting besides number of side effects associated with these treatments on the actual patients. Nanomedicine has evolved over the past few years and became a breakthrough technology for the diagnosis and the treatment of several cancer types. Specifically, the drug is being carried out through carriers called nanoparticles in which the properties of these carriers are very important for the successful treatment of deadly diseases like cancer. In this chapter, we describe the application of nanotechnology and nanomedicines in the diagnosis and treatment of cancer. Further, we discuss the targeted-nanodrug delivery to cancer cells in a broad context. Moreover, we provide a glimpse on marketed nanomedicines available for the management of cancer.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Nanomedicine for Treating Specific Disorders

Nächstes Kapitel Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery

Abdulkareem, I., & Zurmi, I. (2012). Review of hormonal treatment of breast cancer. Nigerian Journal of Clinical Practice, 15, 9–14. https://doi.org/10.4103/1119-3077.94088.CrossRef

Agarwal, S., Sane, R., Oberoi, R., et al. (2011). Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Reviews in Molecular Medicine, 13, 1–27. https://doi.org/10.1017/S1462399411001888.CrossRef

Agemy, L., Friedmann-Morvinski, D., Kotamraju, V. R., et al. (2011). Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proceedings of National Academy of Sciences, 108, 17450–17455. https://doi.org/10.1073/pnas.1114518108.CrossRef

Akilo, O. D., Choonara, Y. E., Strydom, A. M., et al. (2016). AN in vitro evaluation of a carmustine-loaded Nano-co-Plex for potential magnetic-targeted intranasal delivery to the brain. International Journal of Pharmaceutics, 500, 196–209. https://doi.org/10.1016/j.ijpharm.2016.01.043.CrossRef

Amer, M. H. (2014). Gene therapy for cancer: present status and future perspective. Molecular and Cellular Therapies, 2, 1–19. https://doi.org/10.1186/2052-8426-2-27.CrossRef

Anselmo, A. C., & Mitragotri, S. (2016). Nanoparticles in the clinic. Bioengineering Translational Medicine, 1, 10–29. https://doi.org/10.1002/btm2.10003.CrossRef

Arnida, M. A., & Ghandehari, H. (2010). Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: A comparative study of rods and spheres. Journal of Applied Toxicology, 30, 212–217. https://doi.org/10.1002/jat.1486.CrossRef

Arranja, A. G., Pathak, V., Lammers, T., & Shi, Y. (2017). Tumor-targeted nanomedicines for cancer theranostics. Pharmacological Research, 115, 87–95. https://doi.org/10.1016/j.phrs.2016.11.014.CrossRef

Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., et al. (2011). Assessment of the evolution of cancer treatment therapies. Cancers (Basel)., 3, 3279–3330. https://doi.org/10.3390/cancers3033279.CrossRef

Blagosklonny, M. V. (2003). Targeting cancer cells by exploiting their resistance. Trends in Molecular Medicine, 9, 307–312. https://doi.org/10.1016/S1471-4914(03)00111-4.CrossRef

Bobo, D., Robinson, K. J., Islam, J., et al. (2016). Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharmaceutical Research, 33, 2373–2387. https://doi.org/10.1007/s11095-016-1958-5.CrossRef

Bourzac, K. (2016). News feature: Cancer nanomedicine, reengineered. Proceedings of National Academy of Sciences, 113, 12600–12603. https://doi.org/10.1073/pnas.1616895113.CrossRef

Brown, J. S., Sundar, R., & Lopez, J. (2018). Combining DNA damaging therapeutics with immunotherapy: More haste, less speed. British Journal of Cancer, 118, 312–324. https://doi.org/10.1038/bjc.2017.376.CrossRef

Cai, W., Gao, T., Hong, H., & Sun, J. (2008). Applications of gold nanoparticles in cancer nanotechnology. Nanotechnology, Science and Applications, 1, 17–32. https://doi.org/10.2147/NSA.S3788.CrossRef

Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009). Therapeutic antibodies: Successes, limitations and hopes for the future. British Journal of Pharmacology, 157, 220–233. https://doi.org/10.1111/j.1476-5381.2009.00190.x.CrossRef

Chang, T. C., Shiah, H. S., Yang, C. H., et al. (2015). Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemotherapy and Pharmacology, 75, 579–586. https://doi.org/10.1007/s00280-014-2671-x.CrossRef

Cullis, J., Siolas, D., Avanzi, A., et al. (2017). Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunology Research, 5, 182–190. https://doi.org/10.1158/2326-6066.CIR-16-0125.CrossRef

Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148, 135–146. https://doi.org/10.1016/j.jconrel.2010.08.027.CrossRef

Das, S. K., Menezes, M. E., Bhatia, S., et al. (2015). Gene therapies for cancer: Strategies, challenges and successes. Journal of Cellular Physiology, 230, 259–271. https://doi.org/10.1002/jcp.24791.CrossRef

David, A. (2017). Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Advanced Drug Delivery Reviews, 119, 120–142. https://doi.org/10.1016/j.addr.2017.05.006.CrossRef

Elizondo, E., Moreno, E., Cabrera, I., et al. (2011). Liposomes and other vesicular systems: Structural characteristics, methods of preparation, and use in nanomedicine. Progress in Molecular Biology and Translational Science, 104, 1–52. https://doi.org/10.1016/B978-0-12-416020-0.00001-2.CrossRef

Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. Journal of Controlled Release, 157, 168–182. https://doi.org/10.1016/j.jconrel.2011.07.031.CrossRef

Ernsting, M. J., Murakami, M., Undzys, E., et al. (2012). A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. Journal of Controlled Release, 162, 575–581. https://doi.org/10.1016/j.jconrel.2012.07.043.CrossRef

Falzone, L., Salomone, S., & Libra, M. (2018). Evolution of cancer pharmacological treatments at the turn of the third millennium. Frontiers in Pharmacology, 9, 1–26. https://doi.org/10.3389/fphar.2018.01300.CrossRef

Farokhzad, O. C., Cheng, J., Teply, B. A., et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of National Academy of Sciences, 103, 6315–6320. https://doi.org/10.1073/pnas.0601755103.CrossRef

Firdhouse, M. J., & Lalitha, P. (2013). Biosynthesis of silver nanoparticles using the extract of Alternanthera sessilis-antiproliferative effect against prostate cancer cells. Cancer Nanotechnology, 4, 137–143. https://doi.org/10.1007/s12645-013-0045-4.CrossRef

Frenkel, V. (2008). Ultrasound mediated delivery of drugs and genes to solid tumors. Advanced Drug Delivery Reviews, 60, 1193–1208. https://doi.org/10.1016/j.addr.2008.03.007.CrossRef

Gardikis, K., Hatziantoniou, S., Signorelli, M., et al. (2010). Thermodynamic and structural characterization of Liposomal-Locked in-Dendrimers as drug carriers. Colloids Surfaces B Biointerfaces, 81, 11–19. https://doi.org/10.1016/j.colsurfb.2010.06.010.CrossRef

Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005). The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 172, 1487–1490. https://doi.org/10.1164/rccm.200504-613PP.CrossRef

Gianni, L., Pienkowski, T., Im, Y.-H., et al. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. The lancet Oncology, 17, 791–800. https://doi.org/10.1016/S1470-2045(16)00163-7.CrossRef

Gulati, K., Aw, M. S., & Losic, D. (2012). Nanoengineered drug-releasing Ti wires as an alternative for local delivery of chemotherapeutics in the brain. International Journal of Nanomedicine, 7, 2069–2076. https://doi.org/10.2147/IJN.S29917.CrossRef

Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015). Nanoparticle uptake: The phagocyte problem. Nano Today, 10, 487–510. https://doi.org/10.1016/j.nantod.2015.06.006.CrossRef

Hassanpour, S. H., & Dehghani, M. (2017). Review of cancer from perspective of molecular. Journal of Cancer Research and Practice, 4, 127–129. https://doi.org/10.1016/j.jcrpr.2017.07.001.CrossRef

Housman, G., Byler, S., Heerboth, S., et al. (2014). Drug resistance in cancer: An overview. Cancers (Basel), 6, 1769–1792. https://doi.org/10.3390/cancers6031769.CrossRef

Jaganathan, H., & Godin, B. (2012). Biocompatibility assessment of Si-based nano- and micro-particles. Advanced Drug Delivery Reviews, 64, 1800–1819. https://doi.org/10.1016/j.addr.2012.05.008.CrossRef

Jantscheff, P., Esser, N., Graeser, R., et al. (2009). Liposomal gemcitabine (GemLip)—efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. Prostate, 69, 1151–1163. https://doi.org/10.1002/pros.20964.CrossRef

Jiang, X., Xin, H., Ren, Q., et al. (2014). Nanoparticles of 2-deoxy-d-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials, 35, 518–529. https://doi.org/10.1016/j.biomaterials.2013.09.094.CrossRef

Kolishetti, N., Dhar, S., Valencia, P. M., et al. (2010). Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proceedings of National Academy of Sciences, 107, 17939–17944. https://doi.org/10.1073/pnas.1011368107.CrossRef

Kroon, J., Metselaar, J. M., Storm, G., & van der Pluijm, G. (2014). Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treatment Reviews, 40, 578–584. https://doi.org/10.1016/j.ctrv.2013.10.005.CrossRef

Kumar, S. R. P., Markusic, D. M., Biswas, M., et al. (2016). Clinical development of gene therapy: Results and lessons from recent successes. Therapy-Methods & Clinical Development, 3, 1–11. https://doi.org/10.1038/mtm.2016.34.CrossRef

Leece, R., Xu, J., Ostrom, Q. T., et al. (2017). Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. Neuro Oncology, 19, 1553–1564. https://doi.org/10.1093/neuonc/nox091.CrossRef

Li, H.-F., Wu, C., Xia, M., et al. (2015). Targeted and controlled drug delivery using a temperature and ultra-violet responsive liposome with excellent breast cancer suppressing ability. RSC Advances, 5, 27630–27639. https://doi.org/10.1039/C5RA01553G.CrossRef

Li, H., Jin, H., Wan, W., et al. (2018). Cancer nanomedicine: mechanisms, obstacles and strategies. Nanomedicine, 23, 1639–1656. https://doi.org/10.2217/nnm-2018-0007.CrossRef

Lin, S. H., & Kleinberg, L. R. (2008). Carmustine wafers: Localized delivery of chemotherapeutic agents in CNS malignancies. Expert Review of Anticancer Therapy, 8, 343–359. https://doi.org/10.1586/14737140.8.3.343.CrossRef

Liu, L., Ghaemi, A., Gekle, S., & Agarwal, S. (2016). One-component dual actuation: Poly(NIPAM) can actuate to stable 3D forms with reversible size change. Advanced Materials, 28, 9792–9796. https://doi.org/10.1002/adma.201603677.CrossRef

Liu, P., Wang, Z., Brown, S., et al. (2014). Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget, 5, 7471–7485. https://doi.org/10.18632/oncotarget.2166.CrossRef

Luqmani, Y. A. (2005). Mechanisms of drug resistance in cancer chemotherapy. Medical Principles and Practice, 14, 35–48. https://doi.org/10.1159/000086183.CrossRef

Mahmoudi, M., Lynch, I., Ejtehadi, M. R., et al. (2011). Protein − nanoparticle interactions: Opportunities and challenges. Chemical Reviews, 111, 5610–5637. https://doi.org/10.1021/cr100440g.CrossRef

Marquette, C., & Nabell, L. (2012). Chemotherapy-resistant metastatic breast cancer. Current Treatment Options in Oncology, 13, 263–275. https://doi.org/10.1007/s11864-012-0184-6.CrossRef

Meyers, J. D., Doane, T., Burda, C., & Basilion, J. P. (2013). Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond), 8, 123–143. https://doi.org/10.2217/nnm.12.185.CrossRef

Mody, V. V., Siwale, R., Singh, A., & Mody, H. R. (2010). Introduction to metallic nanoparticles. Journal of Pharmacy and Bioallied Sciences, 2, 282–289. https://doi.org/10.4103/0975-7406.72127.CrossRef

Montanari, M., Fabbri, F., Rondini, E., et al. (2012). Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori Journal, 98, 696–701. https://doi.org/10.1700/1217.13491.CrossRef

Mross K, Kratz F (2011) Limits of conventional cancer chemotherapy. In Drug delivery in oncology: From basic research to cancer therapy (vol. 1, pp. 1–31). https://doi.org/10.1002/9783527634057.ch1

Muntimadugu, E., Kumar, R., Saladi, S., et al. (2016). CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surfaces B Biointerfaces, 143, 532–546. https://doi.org/10.1016/j.colsurfb.2016.03.075.CrossRef

Mylonakis, N., Athanasiou, A., Ziras, N., et al. (2010). Phase II study of liposomal cisplatin (Lipoplatin^TM) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer, 68, 240–247. https://doi.org/10.1016/j.lungcan.2009.06.017.CrossRef

Nabipour, I., & Assadi, M. (2015). Converging technologies: Shaping the future of medicine. Iranian South Medical Journal, 17, 1045–1067. http://ismj.bpums.ac.ir/article-1-623-en.html

Nance, E., Zhang, C., Shih, T.-Y., et al. (2014). Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano, 8, 10655–10664. https://doi.org/10.1021/nn504210g.CrossRef

Noy, R., & Pollard, J. W. (2014). Tumor-Associated macrophages: From mechanisms to therapy. Immunity, 41, 49–61. https://doi.org/10.1016/j.immuni.2014.06.010.CrossRef

Oiseth, S. J., & Aziz, M. S. (2017). Cancer immunotherapy: A brief review of the history, possibilities, and challenges ahead. Journal Cancer Metastasis and Treatment, 3, 250–261. https://doi.org/10.20517/2394-4722.2017.41.CrossRef

Otsuka, H., Nagasaki, Y., & Kataoka, K. (2012). PEGylated nanoparticles for biological and pharmaceutical applications. Advanced Drug Delivery Reviews, 64, 246–255. https://doi.org/10.1016/j.addr.2012.09.022.CrossRef

Owens, D. E., & Peppas, N. A. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 307, 93–102. https://doi.org/10.1016/j.ijpharm.2005.10.010.CrossRef

Pal, S. L., Jana, U., Manna, P. K., et al. (2011). Nanoparticle: An overview of preparation and characterization. Journal of Applied Pharmaceutical Science, 1, 228–234.

Peer, D., Karp, J. M., Hong, S., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2, 751–760. https://doi.org/10.1038/nnano.2007.387.CrossRef

Perrault, S. D., Walkey, C., Jennings, T., et al. (2009). Mediating tumor targeting efficiency of nanoparticles through design. Nano Letters, 9, 1909–1915. https://doi.org/10.1021/nl900031y.CrossRef

Pham, E., Yin, M., Peters, C. G., et al. (2016). Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle–drug conjugate, in treatment of metastatic triple-negative breast cancer. Cancer Research, 76, 4493–4503. https://doi.org/10.1158/0008-5472.CAN-15-3435.CrossRef

Qian, L., Zheng, J., Wang, K., et al. (2013). Cationic core–shell nanoparticles with carmustine contained within O6-benzylguanine shell for glioma therapy. Biomaterials, 34, 8968–8978. https://doi.org/10.1016/j.biomaterials.2013.07.097.CrossRef

Ranganath, S. H., Fu, Y., Arifin, D. Y., et al. (2010). The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials, 31, 5199–5207. https://doi.org/10.1016/j.biomaterials.2010.03.002.CrossRef

Reddy, G. R., Bhojani, M. S., McConville, P., et al. (2006). Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clinical Cancer Research, 12, 6677–6686. https://doi.org/10.1158/1078-0432.CCR-06-0946.CrossRef

Sandanaraj, B. S., Gremlich, H.-U., Kneuer, R., et al. (2010). Fluorescent nanoprobes as a biomarker for increased vascular permeability: Implications in diagnosis and treatment of cancer and inflammation. Bioconjugate Chemistry, 21, 93–101. https://doi.org/10.1021/bc900311h.CrossRef

Sengupta, S., & Kulkarni, A. (2013). Design principles for clinical efficacy of cancer nanomedicine: A look into the basics. ACS Nano, 7, 2878–2882. https://doi.org/10.1021/nn4015399.CrossRef

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17, 20–37. https://doi.org/10.1038/nrc.2016.108.CrossRef

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7–30. https://doi.org/10.3322/caac.21442.CrossRef

Singh, P. K., Doley, J., Kumar, G. R., et al. (2012). Oncolytic viruses & their specific targeting to tumour cells. Indian Journal of Medical Research, 136, 571–584.

Sosnik, A., & Carcaboso, A. M. (2014). Nanomedicines in the future of pediatric therapy. Advanced Drug Delivery Reviews, 73, 140–161. https://doi.org/10.1016/j.addr.2014.05.004.CrossRef

Stephen, Z. R., Kievit, F. M., Veiseh, O., et al. (2014). Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors. ACS Nano, 8, 10383–10395. https://doi.org/10.1021/nn503735w.CrossRef

Sun, T., Zhang, Y. S., Pang, B., et al. (2014). Engineered nanoparticles for drug delivery in cancer therapy. Angewandte Chemie International Edition, 53, 12320–12364. https://doi.org/10.1002/anie.201403036.CrossRef

Surendiran, A., Sandhiya, S., Pradhan, S. C., & Adithan, C. (2009). Novel applications of nanotechnology in medicine. Indian Journal of Medical Research, 130, 689–701.

Swaminathan, S. K., Roger, E., Toti, U., et al. (2013). CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. Journal of Controlled Release, 171, 280–287. https://doi.org/10.1016/j.jconrel.2013.07.014.CrossRef

Sykes, E. A., Chen, J., Zheng, G., & Chan, W. C. W. (2014). Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano, 8, 5696–5706. https://doi.org/10.1021/nn500299p.CrossRef

Thangapazham, R. L., Puri, A., Tele, S., et al. (2008). Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. International Journal of Oncology, 32, 1119–1123. https://doi.org/10.3892/ijo.32.5.1119.CrossRef

Tiwary, S., Morales, J. E., Kwiatkowski, S. C., et al. (2018). Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Scientific Reports, 8, 1–13. https://doi.org/10.1038/s41598-018-26636-6.CrossRef

Torre, L. A., Islami, F., Siegel, R. L., et al. (2017). Global cancer in women: Burden and trends. Cancer Epidemiology, Biomarkers and Prevention, 26, 444–457. https://doi.org/10.1158/1055-9965.EPI-16-0858.CrossRef

Tzeng, S. Y., & Green, J. J. (2013). Therapeutic nanomedicine for brain cancer. Therapeutic Delivery, 4, 687–704. https://doi.org/10.4155/tde.13.38.CrossRef

Tzeng, S. Y., Guerrero-Cázares, H., Martinez, E. E., et al. (2011). Non-viral gene delivery nanoparticles based on Poly(β-amino esters) for treatment of glioblastoma. Biomaterials, 32, 5402–5410. https://doi.org/10.1016/j.biomaterials.2011.04.016.CrossRef

van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., et al. (2013). Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews, 65, 1284–1298. https://doi.org/10.1016/j.addr.2013.08.012.CrossRef

van Sluis, R., Bhujwalla, Z. M., Raghunand, N., et al. (1999). In vivo imaging of extracellular pH using 1H MRSI. Magnetic Resonance in Medicine, 41, 743–750. https://doi.org/10.1002/(SICI)1522-2594(199904)41:4%3c743:AID-MRM13%3e3.0.CO;2-Z.CrossRef

Velaei, K., Samadi, N., Barazvan, B., & Soleimani Rad, J. (2016). Tumor microenvironment-mediated chemoresistance in breast cancer. Breast, 30, 92–100. https://doi.org/10.1016/j.breast.2016.09.002.CrossRef

Venditto, V. J., & Szoka, F. C. (2013). Cancer nanomedicines: So many papers and so few drugs! Advanced Drug Delivery Reviews, 65, 80–88. https://doi.org/10.1016/j.addr.2012.09.038.CrossRef

Venkatesan, M., & Jolad, B. (2010). Nanorobots in cancer treatment. In International conference on “Emerging trends in robotics and communication technologies”, INTERACT-2010 (pp 258–264). https://doi.org/10.1109/INTERACT.2010.5706154

Weiner, George J. (2015). Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer, 15, 361–370. https://doi.org/10.1038/nrc3930.CrossRef

Werner, M. E., Cummings, N. D., Sethi, M., et al. (2013). Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. International Journal of Radiation Oncology* Biology* Physics, 86, 463–468. https://doi.org/10.1016/j.ijrobp.2013.02.009.CrossRef

Wirth, T., & Ylä-Herttuala, S. (2014). Gene therapy used in cancer treatment. Biomedicines, 2, 149–162. https://doi.org/10.3390/biomedicines2020149.CrossRef

Xu, X., Ho, W., Zhang, X., et al. (2015). Cancer nanomedicine: From targeted delivery to combination therapy. Trends in Molecular Medicine, 21, 223–232. https://doi.org/10.1016/j.molmed.2015.01.001.CrossRef

Yang, C., Chan, K. K., Lin, W.-J., et al. (2017). Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine. Nano Research, 10, 3049–3067. https://doi.org/10.1007/s12274-017-1521-7.CrossRef

Yang, L., Zhang, X., Ye, M., et al. (2011). Aptamer-conjugated nanomaterials and their applications. Advanced Drug Delivery Reviews, 63, 1361–1370. https://doi.org/10.1016/j.addr.2011.10.002.CrossRef

Zhang, H. (2016). Onivyde for the therapy of multiple solid tumors. OncoTargets and therapy, 9, 3001–3007. https://doi.org/10.2147/OTT.S105587.CrossRef

Zhang, J., Jiang, C., Figueiró Longo, J. P., et al. (2018). An updated overview on the development of new photosensitizers for anticancer photodynamic therapy. Acta Pharmaceutica Sinica B, 8, 137–146. https://doi.org/10.1016/j.apsb.2017.09.003.CrossRef

Zhang, P., Hu, L., Yin, Q., et al. (2012). Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Molecular Pharmaceutics, 9, 1590–1598. https://doi.org/10.1021/mp200600t.CrossRef

Zhang, Y., Yu, J., Zhang, L., et al. (2016). Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles. Tumor Biology, 37, 2703–2708. https://doi.org/10.1007/s13277-015-4106-7.CrossRef

Zou, L., Wang, H., He, B., et al. (2016). Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics, 6, 762–772. https://doi.org/10.7150/thno.14988.CrossRef

Titel: Nanomedicines in Cancer Therapy
verfasst von: Enas Abu-Qudais
Balakumar Chandrasekaran
Sara Samarneh
Ghadir Kassab
Verlag: Springer International Publishing
Buch: Integrative Nanomedicine for New Therapies
Print ISBN: 978-3-030-36259-1

Electronic ISBN: 978-3-030-36260-7

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/978-3-030-36260-7_12

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht